Subscribe

GI Cancers

Barcelona, Spain—In the REACH trial evaluating ramucirumab (Cyramza) as second-line treatment in patients with advanced hepatocellular carcinoma after first-line therapy with sorafenib (Nexavar), overall survival (OS) was improved in the subgroup population with baseline α-fetoprotein of ≥400 ng/mL (Child-Pugh class A). The OS benefits in the overall population (Child-Pugh classes A and B) did not reach significance, said lead investigator Andrew X. Zhu, MD, PhD, Massachusetts General Hospital Cancer Center, Boston.
Barcelona, Spain—The first randomized study prospectively investigating the efficacy of radiofrequency ablation (RFA) added to standard systemic treatment in patients with unresectable colo­rectal cancer (CRC) liver metastases revealed progression-free survival (PFS) and overall survival (OS) benefits, according to Theo J.M. Ruers, MD, PhD, Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam.
Barcelona, Spain—Controlling and minimizing nausea and vomiting enables patients with cancer to continue their chemotherapy. A clinical trial reported at the 2015 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer shows that the newly approved agent aprepitant (Emend), an oral neurokinin (NK)1 antagonist, improved antiemetic control in patients with colorectal cancer (CRC) who were receiving oxaliplatin-based chemotherapy, according to Junichi Nishimura, MD, Assistant Professor, Osaka University, Japan.
An apple a day keeps the doctor away. And now it seems that 4 cups of coffee a day may reduce recurrence and death in patients with stage III colon cancer after surgical resection and adjuvant chemotherapy, according to a study led by Brendan J. Guercio, MD, Harvard Medical School, Boston.

Results 1 - 4 of 4
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology